Status:
NOT_YET_RECRUITING
Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV
Lead Sponsor:
PT Bio Farma
Conditions:
Antibody Typhoid Vaccine
Eligibility:
All Genders
6-60 years
Brief Summary
Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi...
Detailed Description
Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi...
Eligibility Criteria
Inclusion
- Healthy
- Subject/Parents/legal guardian(s) have been informed properly regarding the study and signed the informed consent form/and informed assent form.
- Subject/parents/legal guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.
Exclusion
- History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
Key Trial Info
Start Date :
June 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
624 Patients enrolled
Trial Details
Trial ID
NCT06921460
Start Date
June 15 2025
End Date
December 31 2025
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Child Health Dr. Soetomo Hospital/School of Medicine, Airlangga University, Surabaya, East Java
Jakarta, DKI Jakarta, Indonesia